ArticleJournal of thoracic disease2026
SLFN11 expression as a marker of small cell lung cancer vulnerability to combined PARP inhibitors and immune checkpoint inhibitors during maintenance.
Jean-Louis PujolPubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.